Abstract
In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Current Cancer Drug Targets
Title: Novel Epigenetic Targets in Lymphoproliferative Disorders
Volume: 8 Issue: 5
Author(s): Julio Delgado
Affiliation:
Keywords: DNA methylation, Histone acetylation, Demethylating agents, Histone deacetylase inhibitors, Non-Hodgkin's lymphoma, Hodgkin's lymphoma, Chronic lymphocytic leukemia
Abstract: In addition to well-established genetic abnormalities -particularly gene mutations, deletions or translocations -, epigenetic abnormalities are also implicated in the development and progression of hematological malignancies. As such, the constitutive pattern of DNA methylation and histone acetylation observed in normal hematopoietic cells is remarkably altered in both myeloid and lymphoid tumors. Recent advances in the understanding of these transcriptional and post-transcriptional mechanisms in normal B and T cells as well as malignant lymphoid cells have been instrumental in the development of novel diagnostic markers, prognostic classification and targeted therapeutic approaches. This review focuses on the most important epigenetic alterations discovered in lymphoma-derived cell lines and primary lymphoid tumors and how pharmacologic manipulation of these abnormalities could eventually change the way we treat them in the clinic.
Export Options
About this article
Cite this article as:
Delgado Julio, Novel Epigenetic Targets in Lymphoproliferative Disorders, Current Cancer Drug Targets 2008; 8 (5) . https://dx.doi.org/10.2174/156800908785133222
DOI https://dx.doi.org/10.2174/156800908785133222 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Molecular Replacement in Cancer Therapy: Reversing Cancer Metabolic and Mitochondrial Dysfunction, Fatigue and the Adverse Effects of Cancer Therapy
Current Cancer Therapy Reviews The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management
Recent Patents on Anti-Infective Drug Discovery Statins-Mediated Inhibition of Rho GTPases as a Potential Tool in Anti-Tumor Therapy
Mini-Reviews in Medicinal Chemistry Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets FK506 Binding Proteins as Targets in Anticancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer
Anti-Cancer Agents in Medicinal Chemistry RUNX2 and Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Monoclonal Antibodies in Conjunction with β-Glucans: A Novel Anti- Cancer Immunotherapy
Current Medicinal Chemistry L-Tetrahydropalmatine Induces Apoptosis in EU-4 Leukemia Cells by Down-Regulating X-Linked Inhibitor of Apoptosis Protein and Increases the Sensitivity Towards Doxorubicin
Current Molecular Medicine miR-629-3p Level Significantly Predicts Prognosis in Glioblastoma Patients Treated with Temozolomide Chemotherapy
Current Signal Transduction Therapy Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Targeting the Perpetrator: Breast Cancer Stem Cell Therapeutics
Current Drug Targets Induction of Regulatory T Cells by Dendritic Cells through Indoleamine 2,3- dioxygenase: A Potent Mechanism of Acquired Peripheral Tolerance
Current Medicinal Chemistry The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review
Protein & Peptide Letters The ALK Gene, An Attractive Target for Inhibitor Development
Current Topics in Medicinal Chemistry Editorial [Hot Topic: The Current World Health Organization Classification of the Myeloproliferative and Myelodysplastic/myeloproliferative Neoplasms and Correlation with Pertinent Targeted Therapy (Guest Editor: Cherie H. Dunphy)]
Current Cancer Therapy Reviews Resveratrol as a Chemopreventive Agent: A Promising Molecule for Fighting Cancer
Current Drug Targets